Pappas Capital β Full Portfolio
82 tracked investments Β· listed companies and verified rows first
4DMT is a late-stage biotechnology company that develops gene delivery systems and genetic therapeutics targeting specific tissue types for various diseases.
BiotechHealthtechEmeryville, US
David Kirn(Executive Officer, Director)inDavid Schaffer(Director)inTheresa Janke(Executive Officer)in
BoardSharon Tetlow(Director)Margi McLoughlin(Director)
Co-investorsAmzak HealthBerkeley CatalystBOLD LongevityChiesi VenturesPfizer Venture InvestmentsCasdin Capital+1 more
Cyclerion is a biopharmaceutical company developing therapeutics for neuropsychiatric diseases, with a lead candidate (CYC-126) for treatment-resistant depression that pairs anesthetic agents with a personalized biofeedback-driven device.
BiotechDigital HealthMental HealthCambridge, US
William Huyett(Executive Officer)Mark G. Currie(Executive Officer)inOle Isacson(Director)Stephanie Lovell(Director)Marsha Fanucci(Director)George Conrades(Director)
Co-investorsInvusPolaris Partners
BiotechMorrisville, US
Kevin Gordon(President and Chief Financial Officer)Robert Lippe(Chief Operations Officer)Benjamin Maynor(Senior Vice President, Research and Development)Timothy Albury(Executive Officer)Neal F. Fowler(Chief Executive Officer)
BoardStephen Bloch(Director)in
Co-investorsCanaan Partners
BiotechWaltham, US
John Pallies(Executive Officer)inArlene Morris(Executive Officer, Director)in
BoardDennis Podlesak(Director)Ivor Royston(Director)Luke Evnin, Ph.D.(Director)Kim Kamdar, Ph.D(Director)
Co-investorsForesite CapitalSofinnova VenturesvenBio Partners
Co-investorsSV Health Investors
Aer Therapeutics develops a science-driven therapeutic aimed at eliminating mucus plugs in the lungs to treat muco-obstructive lung diseases such as COPD and asthma.
BiotechHealthtechMedical DevicesRaleigh, US
Thomas Mathers(Executive Officer, Director)inJames Shaffer(Executive Officer, Director)John Fahy(Director)in
BoardChristy Shaffer(Director)inRishi Gupta(Director)Tim Shannon(Director)in
Co-investorsHatteras Venture PartnersOrbiMedCanaan Partners
BiotechSan Mateo, US
Anthony Ford(Executive Officer)inMichael Kitt(Executive Officer)inKathleen Sereda Glaub(Executive Officer, Director)in
BoardKevin Starr(Director)inArthur Pappas(Director)Liam Ratcliffe(Director)
Co-investorsDomain AssociatesFidelity InvestmentsJennison AssociatesThird Rock Ventures
Developing broad-spectrum antifungal agents for invasive fungal infections.
BiotechSan Diego, US
Mitchell Mutz(Executive Officer, Director)
BoardChrysa Mineo(Director)Jack Florio(Director)Elaine Heron(Director)Santosh Vetticaden(Director)Karen Talmadge(Director)
Co-investorsNew Enterprise Associates (NEA)RiverVest Venture PartnersSofinnova VenturesSofinnova Venture Partners
Developing products for diseases associated with inflammation.
BiotechHayward, US
May Liu(Executive Officer)
Co-investorsSofinnova Ventures
Co-investorsHemi Ventures, Llc
Co-investorsPfizer Venture Investments
BiotechSan Diego, US
Fred H. Gage(Director)
BoardCharles W. III Newhall(Director)David Thompson(Director)Carl Goldfischer(Director)Arthur Pappas(Director)
BiotechRedwood City, US
Mark Monane(Executive Officer)Gwen R. Carscadden(Executive Officer)David L. Levison(Executive Officer, Director)Deborah L. Kilpatrick(Executive Officer)Robert F. Werner(Executive Officer)Douglas T. Ross(Executive Officer)
Chimerix is a biopharmaceutical company developing therapies for rare diseases and cancers, with a focus on advancing treatments through biomarker-driven approaches and precision medicine.
BiotechHealthtechMedical DevicesDurham, US
Mike Sherman(Chief Executive Officer and President)W. Garrett Nichols(Chief Medical Officer)Michael A. Alrutz(Executive Officer)Randall Lanier(Chief Science Officer)Roy W. Ware(Chief Manufacturing and Technology Officer)Heather Knight-Trent(Vice President of Regulatory Affairs)
Co-investorsAisling CapitalAlta PartnersAsset Management CompanyCanaan PartnersFrazier Life SciencesSanderling Ventures
BiotechDurham, US
Bernice Kuca(Executive Officer)Mathers P. Thomas(Executive Officer, Director)Nadia Rupniak(Executive Officer)Timothy C. Gupton(Executive Officer)
BoardJesse I. Treu(Director)inRichard J. Markham(Director)
Co-investorsDomain AssociatesTVM CapitalTVM Capital Life Science
CuraSen Therapeutics is a privately funded biopharmaceutical company developing treatments that selectively activate adrenergic receptors in the brain to restore noradrenergic signaling.
BiotechHealthtech
Anthony Fordin
Co-investorsAlta PartnersLongitude Capitalabrdn plcIntermediate Capital GroupJohnson & Johnson Innovation β JJDCNew Leaf Venture Partners+2 more
Emerald BioAgriculture develops biology-based products and solutions using advanced biomanufacturing processes for plant, animal, and human health across various markets.
AgTechBiotechCleantechDeep TechHealthtechNew MaterialsKennett Square, US
Enlaza Therapeutics develops covalent protein therapeutics using its War-Lock technology, which incorporates proprietary unnatural amino acids into protein drugs so they form irreversible covalent bonds with disease-related targets.
BiotechDeep TechSan Diego, US
Sergio Duron(Co-Founder & Chief Executive Officer)inSanford Madigan(Co-Founder, President & Chief Business Officer)inAnaleah Heidt(Chief Scientific Officer)in
BoardMarcos Milla(Director)Jay Lichter(Director)Tighe Reardon(Executive Officer)
Co-investorsFrazier Life SciencesLightspeed Venture PartnersSamsara BioCapitalAvalon BioVenturesPfizer Venture InvestmentsOrbiMed
BiotechMorrisville, US
Ben Yerxa(Executive Officer)inEric Linsley(Executive Officer)in
BoardEd Mathers(Director)inStephen Bloch(Director)inSeth Rudnick(Director)inNeal Fowler(Director)
Co-investorsNew Enterprise Associates (NEA)Canaan Partners
BiotechEast Providence, US
Manny Avila(Executive Officer, Director)inDirk Kuyper(Executive Officer, Director)inRobert Rabiner(Executive Officer)
BoardDaniel Omstead(Director)Fouad Azzam(Director)Rajeev Dadoo(Director)
Co-investorsLife Sciences Partners
BiotechMorrisville, US
Marc Banjak(Executive Officer)Matthew W. Farber(Executive Officer)William G. Nichols(Executive Officer)Matthew R. Stober(Executive Officer, Director)
BoardRobert Bonczek(Director)Raymond Cheong(Director)
BiotechSouth San Francisco, US
John F. Fowler(Executive Officer, Director)inChristopher J. Kirk(Executive Officer, Director)
BoardDr. Gerald Chan(Director)Dr. Jean-Pierre Sommadossi(Director)
Co-investorsBay City CapitalChiesi VenturesSolasta VenturesEcoR1 CapitalQiming Venture Partners
Medical product company using NMR technology to develop diagnostic tests for cardiovascular, metabolic and other diseases.
Co-investorsHavencrest Capital Management
BiotechBothell, US
J. Michael French(Executive Officer, Director)Richard T. Ho(Executive Officer)
BoardR. John Fletcher(Director)Donald A. Williams(Director)Stefan Loren(Director)Philip C. Ranker(Director)
This is a policy/advocacy page from the National Venture Capital Association (NVCA) about protecting foreign investment into U.S. venture funds and startups, addressing CFIUS regulations.
Washington, US
Milestone Pharmaceuticals is a life sciences company that develops therapies for patients with cardiovascular and other diseases.
BiotechDigital HealthHealthtechMedical DevicesMontreal, US
Ela Borenstein(Director)Francis Plat(Executive Officer)Yves Rosconi(Director)Scott Weiner(Director)Martin Maguire(Executive Officer)Philippe Douville(Executive Officer, Director)
Co-investorsForbion
BiotechMill Valley, US
Nikhilesh Singh, Ph.D.(Director, President, Chief Executive Officer and Treasurer)
BoardMichael Chao(Director)Thomas D. Kiley(Director)
Co-investorsNew Enterprise Associates (NEA)Pappas CapitalTakeda Ventures
Co-investorsLightstone Ventures
BiotechGreenville, US
Kevin Weeks(Executive Officer, Director)Katherine Warner(Executive Officer)Joshua Resnick(Director)Michael Solomon(Director)John Gustofson(Director)
Co-investorsHatteras Venture PartnersIllumina VenturesM VenturesMC Healthcare VenturesSV Health InvestorsDementia Discovery Fund+1 more
Co-investorsDCVC (Data Collective)
Co-investorsAlphi CapitalBain Capital VentureMcWin Capital PartnersMithril Capital ManagementTusk Venture Partners
Clinical-stage company developing targeted therapies for kidney disease.
Co-investorsMC Healthcare Ventures
A biopharmaceutical company developing medicines and vaccines with a focus on clinical research and development for human health.
BiotechSan Diego, US
David Johnson(Executive Officer, Director)Cam Gallagher(Director)Scott L. Glenn(Director)
Co-investorsChiesi VenturesSofinnova VenturesVedanta CapitalOrbiMed
Co-investorsHatteras Venture Partners
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.